CPD-1224

• Description:

  CPD-1224 is an orally effective ALK inhibitor, a derivative of an ALK inhibitor that connects to the cereblon ligand. CPD-1224 targets the EML4-ALK oncogenic fusion protein and degrades both ALK and the mutant forms L1196M/G1202R. CPD-1224 can slow down tumor growth[1].

• UNSPSC:

  12352005

• Target:

  Anaplastic lymphoma kinase (ALK)

• Type:

  Reference compound

• Related Pathways:

  Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/cpd-1224.html

• Purity:

  99.83

• Solubility:

  DMSO : 14.29 mg/mL (ultrasonic; warming; heat to 160°C)

• Smiles:

  ClC1=CN=C(NC2=C(OC)C=C(C3CCN(CC4CN(C5=CC=C6C(C(N(C7CCC(NC7=O)=O)C6=O)=O)=C5)C4)CC3)C(C)=C2)N=C1NC8=C(S(C(C)C)(=O)=O)C=CC=C8

• Molecular Formula:

  C43H47ClN8O7S

• Molecular Weight:

  855.40

• References & Citations:

  [1]Gao Y, et al. Catalytic Degraders Effectively Address Kinase Site Mutations in EML4-ALK Oncogenic Fusions. J Med Chem. 2023 Apr 10.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [2891620-68-9]